Premium
A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma
Author(s) -
Ottnod J. M.,
Smedley R. C.,
Walshaw R.,
Hauptman J. G.,
Kiupel M.,
Obradovich J. E.
Publication year - 2013
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/vco.12057
Subject(s) - medicine , melanoma , retrospective cohort study , oncology , cancer , stage (stratigraphy) , disease control , disease , medical record , surgery , complete response , adverse effect , chemotherapy , cancer research , paleontology , virology , biology
Oral malignant melanoma (OMM) in the dog is often locally aggressive with a high metastatic potential and there are few treatment options that have been demonstrated to improve outcome of this disease. The purpose of this study was to determine whether adjunctive treatment with the Oncept melanoma vaccine affected the outcome of dogs with OMM that had achieved loco‐regional cancer control. Medical records from 45 dogs that presented to the Animal Cancer and Imaging Center were reviewed, including 30 dogs with stage II and III disease. Dogs that received the vaccine did not achieve a greater progression‐free survival, disease‐free interval or median survival time than dogs that did not receive the vaccine.